Crossover Study to Compare Pharmacokinetic Property of SYP-1512 Tab and Revlimid Cap in Healthy Male Volunteers

NCT03208218 · clinicaltrials.gov ↗

PHASE1

Phase

COMPLETED

Status

42

Enrollment

INDUSTRY

Sponsor class

Conditions

Healthy, Male

Interventions

DRUG: SYP-1512
DRUG: Revlimid cap

Sponsor

Samyang Biopharmaceuticals Corporation

Collaborators

[object Object]